Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™

June 25, 2024

https://www.globenewswire.com/news-release/2024/06/25/2903828/26106/en/Nuwellis-Secures-New-Patent-for-Innovative-Pediatric-Continuous-Renal-Replacement-Therapy-Vivian.html

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the recent grant of a new patent from the United States Patent and Trademark Office (USPTO) related to its groundbreaking pediatric continuous renal replacement therapy (CRRT), Vivian™. This patent covers critical advancements that will significantly improve the performance and user experience of Vivian. This is the second of several forthcoming patents for Vivian, underscoring Nuwellis’ commitment to development of novel technology designed to improve treatment options for critically ill children.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.